Loading...

PROK PROKIDNEY CORP US FDA Inspections 8-K Filing

PRKD

PRK

PROKIDNEY CORP

(PROK)

2025 8-K

Show Summary

Summary

Market Expansion

Equity Offerings

Clinical Trials

Primary Offerings

Rights Offerings

Financial Statements

Financial Results

Property Acquisition

Financial Results

Investor Update

Financial Results Announcement

Agreement and Offering

Phase 2 Trial Interim Data ...

Annual General Meeting

Disclosure of Clinical Tria...

Financial Results Announcement

Appointment of Executive Vi...

Financial Results Announcement

Termination of Chief Operat...

Amendment to Separation Agr...

Equity Award Grant

Presentation Update

Sales Agreement with Jeffer...

Amendment to Compensation A...

Departure of Directors

Share Repurchase Agreement

Financial Results Announcement

Presentation Update

Financial Results Announcement

Asset Acquisition

Annual General Meeting

Results of Operations and F...

Results of Operations and F...

Presentation Update

Short Term Incentive Perfor...

Other Special Situation

Regulation FD Disclosure

External Links:

On July 8, 2025, ProKidney Corp. reported topline results from its REGEN-007 study focused on rilparencel for diabetes and chronic kidney disease.

AI Assistant

PROKIDNEY CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.